SCHEMBL1401237

SCHEMBL1401237

O=[C]CCCCCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.63
LMNA P02545 2/20 0.63
NFKB1 P19838 1/20 0.63
PMP22 Q01453 1/20 0.63
HSD17B10 Q99714 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2D6 P10635 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
PTPN7 P35236 3/20 0.56
HMGCR P04035 3/20 0.56
GPR84 Q9NQS5 4/20 0.52
FFAR1 O14842 2/20 0.52
FFAR4 Q5NUL3 2/20 0.52
PPARG P37231 5/20 0.50
PPARD Q03181 5/20 0.50
PPARA Q07869 5/20 0.50
HDAC11 Q96DB2 4/20 0.50
ALDH1A1 P00352 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701316 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL970516 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL7382880 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL6539108 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL3972155 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL3980051 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL1702085 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL374773 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL1654498 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL7292218 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102146-A1 MULTI-TARGET TYROSINE KINASE INHIBITOR SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2023-03-30 US claimed
EP-4108666-A1 MULTI-TARGET TYROSINE KINASE INHIBITOR Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. (CN) 2022-12-28 EP claimed
CN-113336768-B Multi-target tyrosine kinase inhibitor 深圳海王医药科技研究院有限公司 2022-08-19 CN claimed
CN-113336768-A Multi-target tyrosine kinase inhibitor 深圳海王医药科技研究院有限公司 2021-09-03 CN claimed
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF Yamaguchi, Koushi (JP) 2023-04-06 US disclosed
US-20230102146-A1 MULTI-TARGET TYROSINE KINASE INHIBITOR SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2023-03-30 US disclosed
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof Yamaguchi, Kouchi (JP) 2023-01-03 US disclosed
EP-4108666-A1 MULTI-TARGET TYROSINE KINASE INHIBITOR Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. (CN) 2022-12-28 EP disclosed
CN-113336768-B Multi-target tyrosine kinase inhibitor 深圳海王医药科技研究院有限公司 2022-08-19 CN disclosed
EP-3977995-A1 TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS Yamaguchi, Koushi (JP) 2022-04-06 EP disclosed
EP-3900729-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY Yamaguchi, Koushi (JP) 2021-10-27 EP disclosed
EP-3246036-B1 MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME YAMAGUCHI KOUSHI (JP) 2021-10-13 EP disclosed
US-4894366-A Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-01-16 US disclosed
CN-1037155-A Amino acid derivative MERCK PATENT GMBH (DE) 1989-11-15 CN disclosed
EP-0339483-A2 Renin inhbiting amino-acid derivatives MERCK PATENT GmbH (DE) 1989-11-02 EP disclosed
EP-0337334-A2 Renin-inhibiting amino acid derivatives MERCK PATENT GmbH (DE) 1989-10-18 EP disclosed
EP-0051467-B1 HEXITOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1986-08-13 EP disclosed
EP-0184162-A2 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-06-11 EP disclosed
US-4419522-A ANTITUMOR AGENTS CHINOIN GYOGYSZER VEGYESZETI TERMEKEK GYARA RT. (HU) 1983-12-06 US disclosed
EP-0051467-A1 Hexitol derivatives, their preparation and pharmaceutical compositions containing them CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102146-A1 MULTI-TARGET TYROSINE KINASE INHIBITOR LCK, ABL1, DSTYK TSHR 1922/4885LMNA 4857/4885NFKB1 1779/4885
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF PGF, SLC10A1, SLC26A4 TSHR 1982/4885LMNA 2424/4885NFKB1 1572/4885
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof PGF, SLC10A1, SLC26A4 TSHR 2169/4885LMNA 2875/4885NFKB1 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.